Last reviewed · How we verify
Boostrix™-US formulation
Boostrix is a vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.
Boostrix is a vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Booster immunization against diphtheria, tetanus, and pertussis in adolescents and adults aged 10 years and older.
At a glance
| Generic name | Boostrix™-US formulation |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated bacterial vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Boostrix contains inactivated toxoids of diphtheria and tetanus, plus acellular pertussis antigens, which trigger adaptive immune responses without causing disease. Upon vaccination, the immune system generates antibodies and cellular immunity against these three bacterial pathogens, providing protection against infection and disease.
Approved indications
- Booster immunization against diphtheria, tetanus, and pertussis in adolescents and adults aged 10 years and older
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Boostrix™-US formulation CI brief — competitive landscape report
- Boostrix™-US formulation updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI